CIVO for first early rivipansel treatment in OLE phase of study and early placebo treatment in RESET study
Overall population . | ||
---|---|---|
. | OLE early rivipansel (n = 38) . | RESET early placebo (n = 46) . |
Median | 1.83 | 3.79 |
(Q1, Q3) | (0.61, 5.15) | (1.20, 9.06) |
Difference in medians (90% CI) | −1.97 (−2.73 to 0.81) | |
Ratio of medians (90% CI) | 0.71 (0.37-1.34) | |
P value∗ | .2311 (NS) |
Overall population . | ||
---|---|---|
. | OLE early rivipansel (n = 38) . | RESET early placebo (n = 46) . |
Median | 1.83 | 3.79 |
(Q1, Q3) | (0.61, 5.15) | (1.20, 9.06) |
Difference in medians (90% CI) | −1.97 (−2.73 to 0.81) | |
Ratio of medians (90% CI) | 0.71 (0.37-1.34) | |
P value∗ | .2311 (NS) |
Adult population . | ||
---|---|---|
. | OLE early rivipansel (n = 17) . | RESET early placebo (n = 23) . |
Median | 3.45 | 4.99 |
(Q1, Q3) | (1.21, 14.88) | (0.88, 9.49) |
Difference in medians (90% CI) | −1.55 (−7.91 to 4.81) | |
Ratio of medians (90% CI) | 1.09 (0.39-3.04) | |
P value∗ | .9039 (NS) |
Adult population . | ||
---|---|---|
. | OLE early rivipansel (n = 17) . | RESET early placebo (n = 23) . |
Median | 3.45 | 4.99 |
(Q1, Q3) | (1.21, 14.88) | (0.88, 9.49) |
Difference in medians (90% CI) | −1.55 (−7.91 to 4.81) | |
Ratio of medians (90% CI) | 1.09 (0.39-3.04) | |
P value∗ | .9039 (NS) |
Pediatric population (age 6-17 y) . | ||
---|---|---|
. | OLE early rivipansel (n = 21) . | RESET early placebo (n = 23) . |
Median | 1.58 | 2.54 |
(Q1, Q3) | (0.61, 2.25) | (1.20, 8.00) |
Difference in medians (90% CI) | −0.96 (−2.93 to 1.01) | |
Ratio of medians (90% CI) | 0.48 (0.22-1.08) | |
P value∗ | .0718 |
Pediatric population (age 6-17 y) . | ||
---|---|---|
. | OLE early rivipansel (n = 21) . | RESET early placebo (n = 23) . |
Median | 1.58 | 2.54 |
(Q1, Q3) | (0.61, 2.25) | (1.20, 8.00) |
Difference in medians (90% CI) | −0.96 (−2.93 to 1.01) | |
Ratio of medians (90% CI) | 0.48 (0.22-1.08) | |
P value∗ | .0718 |
NS, not significant.
From analysis of covariance in rank-transformed values.